- Home
- / Iovance Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Iovance Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$10.8
2024-10-29
Market Capitalization
$3.3 B
2024-10-29
Revenue
$263.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2M | 164.1M | 263.5M | ||||||||||||
| Cost of goods sold | 10.8M | 124.0M | 173.2M | ||||||||||||
| Gross profit | (9.6M) | 40.1M | 90.3M | ||||||||||||
| Gross profit margin, % | -804.5% | 24.4% | 34.3% | ||||||||||||
| General and administrative expense | 12.4M | 25.6M | 21.3M | 28.4M | 40.8M | 60.2M | 83.7M | 104.1M | 106.9M | 153.0M | 152.3M | ||||
| Operating expense total | 1.8M | 1.7M | 1.3M | 2.7M | 27.9M | 53.6M | 92.9M | 128.3M | 206.9M | 261.9M | 398.9M | 451.0M | 435.4M | 493.7M | |
| Depreciation and amortization | 35.9M | ||||||||||||||
| EBIT | (21.2M) | (8.1M) | (22.6M) | (12.0M) | (27.9M) | (53.6M) | (92.9M) | (128.3M) | (206.9M) | (261.9M) | (342.7M) | (398.9M) | (460.6M) | (395.3M) | (403.4M) |
| EBIT margin, % | -38735.0% | -240.9% | -153.1% | ||||||||||||
| Interest income | 745.0K | 813.0K | 4.7M | 9.3M | 2.4M | 451.0K | 3.0M | 13.0M | 20.3M | 10.3M | |||||
| Interest expense | 151.5K | 1.9M | 444.7K | 200.0K | |||||||||||
| Pre tax profit | (447.5M) | (375.0M) | (393.0M) | ||||||||||||
| Income tax expense | (3.5M) | (2.8M) | (2.1M) | ||||||||||||
| Net Income | (25.7M) | (3.3M) | (25.4M) | (12.0M) | (27.7M) | (52.9M) | (92.1M) | (123.6M) | (197.6M) | (259.6M) | (342.3M) | (396.2M) | (444.0M) | (372.2M) | |
| EPS | (2.5) | (1.9) | (1.3) | (1.1) |